Marshall Wace, LLP Uni Qure N.V. Call Options Transaction History
Marshall Wace, LLP
- $77.3 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding QURE
# of Institutions
154Shares Held
41MCall Options Held
925KPut Options Held
617K-
Vestal Point Capital, LP New York, NY4.75MShares$33.9 Million1.78% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT2.78MShares$19.8 Million0.81% of portfolio
-
Boxer Capital, LLC San Diego, CA2.23MShares$15.9 Million0.58% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny2.19MShares$15.6 Million0.01% of portfolio
-
Abrdn PLC1.93MShares$13.8 Million0.02% of portfolio
About uniQure N.V.
- Ticker QURE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,729,100
- Market Cap $333M
- Description
- uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...